Inovio Pharma (INO) Stock
Fundamentals
Latest news
About Inovio Pharma
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jacqueline E. Shea Ph.D. | CEO, President & Director | 1966 |
| Mr. Peter D. Kies | Chief Financial Officer | 1963 |
| Dr. Michael Sumner B.S., M.B.A., M.D. | Chief Medical Officer & Head of Development | 1965 |
| Dr. Laurent M. Humeau Ph.D. | Chief Scientific Officer & Chairman of the Scientific Advisory Board | 1967 |
| Mr. Robert L. Crotty J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1974 |
| Ms. Jennie Willson | Director of Communications | — |
| Mr. E. J. Brandreth MBA | Senior Vice President of Quality Assurance | — |
| Dr. Jeffrey Skolnik M.D. | Senior Vice President of Clinical Development | — |
| Mr. Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing & Clinical Supply Management | — |
| Mr. Shawn D. Bridy M.A., M.B.A. | Senior Vice President of Business Development | — |



